Treatment of disseminated aspergillosis with voriconazole/liposomal amphotericin B in a child with leukemia [2]

Pediatric Blood and Cancer

Volumn 45, Issue 7, 2005, Pages 1003-1004

  Athanassiadou, Fani ^a   Tragiannidis, Athanassios ^a   Kourti, Maria ^a   Papageorgiou, Theodotis ^a   Velegraki, Aristea ^b   Kalogera, Anna ^c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; VORICONAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBIOTIC THERAPY; ASPERGILLOSIS; BLOOD BRAIN BARRIER; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEBRILE NEUTROPENIA; HUMAN; LETTER; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CHILD, PRESCHOOL; HUMANS; LEUKEMIA, B-CELL, ACUTE; MALE; PYRIMIDINES; TOMOGRAPHY, X-RAY COMPUTED; TRIAZOLES;

EID: 27644508712     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20515     Document Type: Letter

References (4)

1. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002;34:7-14.
2. Swu-Jane L, Schranz J, Teutsch M. Aspergillosis case-fatality rate: Systemic review of the literature. Clin Infect Dis 2001;32:358-366.
3. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415.
4. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003;37:728-732.